Changzhou Qianhong Biopharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
April 09, 2021 at 01:31 pm
Share
Changzhou Qianhong Biopharma CO.,LTD announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 1,667.606 million compared to CNY 1,675.153 million a year ago. Operating loss was CNY 164.758 million compared to operating Income of CNY 300.240 million a year ago. Net loss was CNY 132.019 million compared to net income of CNY 262.561 million a year ago. Basic loss per share from continuing operations was CNY 0.11 compared to basic earnings per share from continuing operations of CNY 0.21 a year ago.
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.
CHANGZHOU QIANHONG BIOPHARMA CO.,LTD 
